Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Evolus

Vaccinex Inc

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechnology company that develops vaccines.

Why Novavax, Vaccinex, Evolus Are Trading Higher Today

Shares of Novavax jumped 10% on Friday after the biotech firm announced that it would supply over 1.1 billion doses of COVID-19 vaccines as part of a global initiative.  The Gaithersburg, Maryland-based company late Thursday unveiled a memorandum of understanding with GAVI, the Global Alliance for Vaccines and Immunization, to provide its vaccine to the COVID-19 Vaccines Global Access (COVAX) initiative in a global push to guarantee fair and equitable vaccine distribution.

Novavax jumps 10% on deal to provide over 1 billion doses of its COVID-19 vaccine globally

Novavax, Inc. (NASDAQ: NVAX) shares raced to an all-time $331.68 on Feb. 9 before beginning to lose steam. Shares have declined for seven consecutive sessions since then, but a positive release from the company is lifting the stock.

Novavax On Track To Snap Losing Streak On Massive Vaccine Supply Deal

This stock isn't a sure thing. But it's a lot closer to being one than Ocugen.

Forget Ocugen! Here's a COVID Stock That Could Make You Richer Quicker

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax' recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility. The vaccine doses will be manufactured and distributed globally by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII. NVX-CoV2373 is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom (U.K.), for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from its U.K. trial.

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

AstraZeneca

BioNTech SE

Johnson & Johnson

Pfizer

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Novavax stock has had a stellar run, more than doubling since early January 2021 driven by promising efficacy data for its Covid-19 vaccine. The stock is also up about 30x over the last 12 months.

Is Novavax Stock Too Risky At $260?

This investigational vaccine showed it could handle one of today's biggest risks.

Is Novavax Stock a Good Bet on Coronavirus Vaccines?

Though RNA vaccines may have jumped to the lead, the complexities of the Covid-19 crisis gives NVAX stock some extra room to run even higher. The post Despite Huge Run, There's Still Some Upside for Novavax appeared first on InvestorPlace.

Despite Huge Run, There's Still Some Upside for Novavax

Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

The stock's gains could continue despite a chink in its armor.

1 Green Flag and 1 Red Flag for Novavax's Vaccine Candidate

The biotech's vaccine could be the most effective of all against the most prevalent coronavirus strain.

Why Novavax's COVID Vaccine Results Were So Stellar

Here's Why the Novavax Vaccine May Have to Wait for FDA Authorization

All American adults could potentially be fully vaccinated this year with only Pfizer's and Moderna's vaccines.

Could the U.S. Buying More COVID Vaccines Hurt Johnson & Johnson and Novavax?

It may be behind, but the biotech's clinical trial data looked good.

Novavax Gets the Job Done With its COVID Vaccine

Could Novavax Win U.S. Authorization for Its COVID Vaccine Sooner Than Expected?

The chances look pretty good that the biotech stock will continue its winning ways.

Will Novavax Stock Jump Another 25% This Year?

Novavax, Inc.'s (NASDAQ: NVAX) recent hot streak is continuing, as the stock moved past $300 Monday. What Happened: After ending 2020 on a strong note, shares of Gaithersburg, Maryland-based Novavax have been going from strength to strength in the new year.

Novavax Shares Pass The $300 Mark: Is The Rally Sustainable?

The company's vaccine faced new strains in a real-world setting.

Is Novavax Still a Buy After Doubling in Two Days?

It has been an exciting few days for coronavirus vaccine developer Novavax, Inc. (NASDAQ: NVAX), as continuing vaccine news flow pushes the stock to new highs. Novavax's Breathtaking Run: Novavax was among the best-performing stocks of 2020, gaining about 2,700%.

Novavax's Record Stock Run: What Investors Need To Know

Johnson & Johnson and Novavax asked the Food and Drug Administration to authorize their coronavirus vaccines late Thursday — and both vaccine stocks jumped Friday. The post J&J, Novavax Ask FDA To Authorize Covid Vaccines — Shares Surge Higher appeared first on Investor's Business Daily.

J&J, Novavax Ask FDA To Authorize Covid Vaccines — Shares Surge Higher

Novavax reported 89% efficacy for its COVID-19 vaccine from its UK P3 trial, and the stock has doubled since then.

Novavax's COVID Vaccine May Get U.S. Approval Sooner Than You Think: Here Is Why

Johnson & Johnson's coronavirus vaccine offers one-shot convenience, but Novavax has clear advantages.

Here's Why Novavax Can Beat Johnson & Johnson in the COVID-19 Vaccine Race

Novavax stock has had a stellar run, rising by 117% over the last five trading days. The stock is up a whopping 40x over the last 12 months.

Novavax Stock Doubled Over The Last 5 Days, Will The Rally Continue?

BlackBerry

Fastly

Here's why you might consider adding an enterprise software developer, an edge computing firm, and a coronavirus vaccine developer to your portfolio.

News for Novavax Stock (NVAX)